Anti-L1 CAM as treatment of ovarian and endometrial cancer

  • Category: Diagnostics
  • Investment Status: Advanced
  • Medical Field: Women’s Health
  • Medical Center: Kaplan Medical Center and German Cancer Center, Heidelberg, Germany
  • Inventors: Prof Mina Fogel and Prof Peter Altevogt

Technology: The L1CAM molecule has emerged as a promising new biomarker for the diagnosis and prognosis of human ovarian and endometrial tumors (Fogel M. et al. Lancet 2003).

We generated novel therapeutic antibodies to L1CAM and have demosntrated efficiently prolonged survival, reduced tumor mass and ascites volume by >60% . These findings qualify L1 as a novel, promising target molecule for therapy of patients with L1 positive cancers.